Lima, Peru, 3 January 2023 - MicroPort® has recently received marketing registration approval from the Peruvian General Directorate of Medicines, Supplies and Drugs for its self-developed coronary balloon catheters, the Foxtrot™ Pro Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter, the Foxtrot™ NC PTCA Balloon Catheter, the Firefighter™ PTCA Balloon Catheter, and the Firefighter™ NC Balloon Catheter.
The Foxtrot™ Pro PTCA Balloon Catheter is a rapid-exchange catheter primarily used in PTCA procedures for lesion dilatation before stenting, offering additional solutions for complex lesions with excellent crossability and traceability. The new ultra-long hydrophilic coating significantly improves catheter crossability and pushability for use in the para-anastomotic balloon technique.
The Foxtrot™ NC PTCA Balloon Catheter is used both for pre-dilation of endovascular lesions prior to stent implantation as well as for precise post-dilation of stents after their implantation. A dual-chamber balloon made of high-pressure resistant polymer material and a push rod and connector supported by a single-chamber stainless steel shaft allow for low compliance and a short retraction time. The tip of the catheter has a coaxial double-lumen structure and the outer surface of the catheter is coated with a super-lubricated hydrophilic coating, enabling it to move freely within blood vessels and smoothly access the stenotic lesion area. Additionally, platinum markers ensure higher visibility. These features have contributed to the excellent crossability, traceability and pushability of the catheter.
The Firefighter™ PTCA Balloon Catheter has a minimal profile compared to competitor products of the same size and is made of flexible materials, enabling it to cross stenotic and tortuous lesions multiple times. Despite its extremely small size, it enables surgeons to perform complex maneuvers such as balloon-stent kissing by accommodating two balloon catheters in a 5F introducer catheter.
The Firefighter™ NC Balloon Catheter is a new generation of high-pressure resistant and rapid-exchange balloon catheters. The outer surface of the catheter is coated with a hydrophilic polymer from the front and rear attachment points to the distal end of the product, reducing friction on the surface of the catheter when in contact with water during surgery, thereby facilitating catheter delivery into and across lesion areas. It is suitable for balloon dilatation of stenoses in coronary tracts or coronary bypass bridges to improve myocardial perfusion, as well as for post-balloon dilatation of stents after their implantation.
The Firehawk® Rapamycin Target Eluting Coronary Stent System and the Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System entered the Peruvian market in 2014 and 2022, respectively. The recent approval of multiple balloon dilatation catheters has further enriched the coronary intervention portfolio of MicroPort® in Peru and will contribute to providing an integrated solution for physicians. In the future, MicroPort® will continue to strengthen its efforts in developing the Peruvian market and make more high-quality products available in Peru for the benefit of patients and medical professionals.
Founded in Shanghai in 1998 on the belief that every person has the right to high quality medical treatments, MicroPort Scientific Corporation (“MicroPort®”, stock code: 00853.HK) is today a global medical devices company with over 12,000 employees worldwide. We provide solutions across twelve therapeutic areas, including orthopedics, cardiac rhythm management, electrophysiology and endovascular. At MicroPort®, we are breaking barriers and accelerating access to life-changing solutions with the purpose of prolonging and reshaping the lives of patients everywhere. Our therapeutic solutions are available in more than 100 countries and over 20,000 hospitals around the world, and today, a patient benefits from a MicroPort® solution every six seconds.
More information is available at www.microport.com.